This article reviews the impact of the new pharmaceutical legislation on the development of biotech products. The authors describe in details current and new challenges that will have an impact on the development and preparation of the registration dossier of biologicals.
Download the full publication now
Fill in the form to download the content
publication by
Amanda Gibbons
Director Biologics CMC and Regulatory Science
She is responsible for the design and implementation of strategic development plans, particularly on Chemistry Manufacturing and Control (CMC) aspects of biological products, such as Recombinant, Gene-therapy, Vaccines and Biosimilar Medicinal Products. Her industrial experience in start-ups to large companies gives her a clear understanding of size-specific challenges faced by healthcare professionals.
All our resources 
